13D Filing: DAFNA Capital Management and Stereotaxis Inc. (STXS)

Page 2 of 8 – SEC Filing


CUSIP: 85916J409 SCHEDULE 13D
  1

NAMES OF
REPORTING PERSON

DAFNA Capital Management, LLC

  2

CHECK THE APPROPRIATE BOX IF A MEMBER
OF A GROUP

(a)  ☐        (b)  ☐

  3

SEC USE ONLY

  4

SOURCE OF FUNDS

AF

  5

CHECK BOX IF DISCLOSURE OF LEGAL
PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) OR 2(e)

  6

CITIZENSHIP OR PLACE OF
ORGANIZATION

Delaware

NUMBER OF

SHARES

BENEFICIALLY

OWNED BY

EACH

REPORTING

PERSON

WITH

  7

SOLE VOTING POWER

0

  8

SHARED VOTING POWER

13,680,554 (1)

  9

SOLE DISPOSITIVE POWER

0

10

SHARED DISPOSITIVE POWER

13,680,554 (1)

11

AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

13,680,554 (1)

12

CHECK BOX IF THE AGGREGATE AMOUNT IN
ROW (11) EXCLUDES CERTAIN SHARES

13

PERCENT OF CLASS REPRESENTED BY AMOUNT
IN ROW (11)

23.4%(2)

14

TYPE OF REPORTING PERSON

IA

(1) Consists of shares of common stock (Common Stock) of Stereotaxis, Inc., a Delaware corporation (the Issuer), held by DAFNA LifeScience, L.P. and DAFNA LifeScience Select, L.P., of which DAFNA
Capital Management, LLC, a Delaware limited liability company (DAFNA), is the investment manager and general partner. Excludes shares of Common Stock issuable upon conversion of preferred stock as well as shares of Common Stock issuable
upon exercise of warrants held by DAFNA LifeScience, L.P., DAFNA LifeScience Select, L.P., and DAFNA LifeScience Market Neutral, L.P., (the Funds) as a result of the Beneficial Ownership Limitation described herein. See Item 5 of this
Amendment No. 4 to the Schedule 13D for further details.
(2) See Item 5 of this Amendment No. 4 to the Schedule 13D.

Page 2 of 8

Follow Stereotaxis Inc. (NASDAQ:STXS)